Used in pharmaceutical research as a potent and selective inhibitor of cereblon (CRBN), this compound plays a key role in the development of targeted protein degradation therapies. It serves as a key intermediate in synthesizing analogs of thalidomide and lenalidomide, modified to enhance binding affinity and specificity. Due to its ability to modulate CRBN activity, it is investigated for use in treating hematological cancers such as multiple myeloma and myelodysplastic syndromes. Additionally, its bromo-functionalized aromatic core allows for further chemical derivatization via cross-coupling reactions, enabling rapid exploration of structure-activity relationships in drug discovery programs.